The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy

Current Pharmaceutical Design

Volumn 12, Issue 8, 2006, Pages 977-987

  Calvo, Rosario ^a   Lukas, John C ^b   Rodriguez, Monica ^c   Leal, Nerea ^c   Suarez, Elena ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b PHARSIGHT CORPORATION   (United States)

^c Dynakin SL   (Spain)

Author keywords

AGP variability; PK PD; Protein binding; Unbound drug

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALBUMIN; AMPRENAVIR; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; DOCETAXEL; ETOPOSIDE; FENTANYL; LIDOCAINE; METHADONE; NONSTEROID ANTIINFLAMMATORY AGENT; OROSOMUCOID; PACLITAXEL; PHENYLBUTAZONE; PROPAFENONE; PROPOFOL; PROPRANOLOL; PROTEINASE INHIBITOR; PROTHROMBIN; PYRAZOLE DERIVATIVE; SULFAPHENAZOLE; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ALLOMETRY; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BINDING AFFINITY; CALCULATION; CANCER CHEMOTHERAPY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOGLYCEMIA; IN VITRO STUDY; OUTCOMES RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STATISTICAL ANALYSIS;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; DRUG MONITORING; HIV INFECTIONS; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; NEOPLASMS; OROSOMUCOID; PROTEIN BINDING; SERUM ALBUMIN; SPECIES SPECIFICITY;

EID: 33645971661     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055967     Document Type: Review

References (119)

1. Goldstein A. The interactions of drugs and plasma proteins. Pharmacol Rev 1949; 1: 102-65.
2. Sjöholm I, Ekman B, Kober A, Ljungstedt-Påhlman I, Seiving B, Sjödin T. Binding of drugs to human serum albumin XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Phamacol 1979; 767-77.
3. Danhof M, Hisaoka M, Levy G. Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 1984; 230: 627-31.
4. Ramzam IM, Levy G. Kinetics of drug action in disease states. IX. Effect of experimental renal failure on the pharmacodynamics of theophilline-induced seizures in rats. J Pharmacol Exp Ther 1987; 240: 584-588.
5. Aguilera L, Calvo R, Carlos R. Interaction between thiopental and sodium valproate. And in vitro and in vivo study. Br J Anaesthesia 1986; 58: 1380-83.
6. Kurz H, Trunk H, Weitz B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung 1977; 27: 1373-80.
7. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 1992; 23: 449-68.
8. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentration. Clin Pharmacokinet 1996; 30: 445-62.
9. Koch-Weser J, Sellers EM. Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med 1976; 294: 526-31.
10. Zini R, Riant P, Barre J, Tillement JP. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet 1990; 19: 147-59.
11. Zini R, Riant P, Barre J, Tillement JP. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). Clin Pharmacokinet 1990; 19: 218-29.
12. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984; 9(Suppl 1): 18-26.
13. Costela JL, Jimenez R, Calvo R, Suarez E, Carlos R. Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Acta Anaest Scan 1996; 40: 741-5.
14. Shoeman DW, Azarnoff DL. Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther 1975; 195: 84-6.
15. Boobis SW. Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 1977; 22: 147-53.
16. Erill S, Calvo R, Carlos R. Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharmacol Ther 1980; 27: 612-18.
17. Calvo R, Carlos R, Erill S. Effects of carbamlyation of plasma proteins and competitive displacers on drug binding in uremia. Pharmacology 1982; 24: 248-52.
18. Gatti G, Crema F, Attardo-Parrinello G, Fratino P, Aguzzi F, Perucca E. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987; 9: 389-91.
19. Arredondo G, Suárez E, Calvo R, Vázquez JA, Sanchez Garcia J, Martínez Jordá R. Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J Antimicrobial Chemother 1999; 43: 35-41.
20. Affime M, Reidenberg MM. The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol 1975; 8: 267-9.
21. Perez-Mateo M, Erill S. Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency. Eur J Clin Pharmacol 1977; 11: 225-31.
22. Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977; 296: 1495-7.
23. Christensen LK, Hansen JM, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 1963; 41: 1298-301.
24. Fox S. Potentiation of anticoagulants by pyrazole compounds. J Am Med Ass 1964; 188: 320-321.
25. Aggerler PM, O'Reilly RA, Leomg L, Kowitz PE. Potentiation of anticoagulant effect on warfarin by phenylbutazone. New Engl J Med 1967; 276: 496-501.
26. Reidenberg MM, Erill S. Drug -Protein Binding. Esteve Foundation Symposium I. Clinical Pharmacology and Therapeutics Series. Philadelphia, Praeger 1986; Vol 6.
27. Tillement JP, Lindenbaub E. Protein binding and drug transport. New York, Verlag- Sttutgart 1986.
28. MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989; 16: 65-73.
29. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 1995; 12: 227-33.
30. Sellers EM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 1979; 18: 225-7.
31. Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-8.
32. Zamacona MK, Suarez E, Garcia E, Aguirre C, Calvo R. Significance of lipoproteins in serum binding variations of propofol. Anesth Analg 1998; 87: 1147-51.
33. de la Fuente L, Lukas JC, Vazquez JA, Jauregizar N, Calvo R, Suarez E. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction. Eur J Clin Pharmacol 2002; 58: 615-19.
34. de la Fuente L, Lukas JC, Jauregizar N, Vazquez JA, Calvo R, Suarez E. Prediction of unbound propofol concentrations in a diabetic population. Ther Drug Monit 2002; 24: 689-95.
35. Zamacona MK, Suarez E, Aguilera L, Rodriguez-Sasiain JM, Aguirre C, Calvo R. Serum protein binding of propofol in critically ill patients. Acta Anaest Scan 1997; 41: 1267-72.
36. Leal N, Calvo R, Agrad FZ, Lukas JC, de La Fuente L, Suarez E. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. J Pharm Pharmacol 2005; 57: 317-325.
37. Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharm Ther 2004; 75: 324-30.
38. Holford NH. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287-91.
39. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195-222.
40. Lukas JC, Karikas G, Gazouli M, Kalabalikis P, Hatzis T, Macheras P. Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharm Res 2004; 21: 2074-81.
41. Oellerich M, Shipkova M, Ekkehard S, Wieland E, Weber L, Tonschoff B, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. Ther Drug Monitor 2000; 22: 20-6.
42. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and applications. 3rd Ed. Lippincott Williams & Wilkins, Media. Pennsylvania. 1995.
43. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. 4th Ed. Philadelphia, Lea & Febiger 1991.
44. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435-40.
45. Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 2004; 93: 364-74.
46. Rodriguez M, Carlos MA, Ortega I, Suarez E, Calvo R, Lukas JC. Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. Pharm Res 2002; 19: 858-67.
47. Rodriguez M, Ortega I, Soengas I, Leal N, Suarez E, Calvo R, et al. Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding. J Pharm Sci 2004; 93: 2836-50.
48. Wilkinson GR, Scand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-90.
49. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21.
50. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
51. Piafsky KM, Borga O. Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 1977; 22: 545-9.
52. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1-47.
53. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000; 1482: 157-71
54. Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246-62.
55. Holladay JW, Dewey MJ, Yoo SD. Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels. Pharm Res 1996; 13: 1313-6.
56. Holladay JW, Dewey MJ, Yoo SD. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. Drug Metab Dispos 1998; 26: 20-4.
57. Garcia E, Calvo R, Rodriguez Sasiaín JM, Jimenez R, Troconiz I, Súarez E. Resistance of atracurium in rats with experimental inflammation: role of protein binding. Acta Anaesthesiol Scand 1995; 39: 1019-23.
58. Torres I, Gomez E, Garcia E, Suarez E, Rodriguez Sasiaín JM, Calvo R. Influence of changes in protein binding on the central activity of antidepressants. J Pharm Pharmacol 1992; 44: 531-3.
59. Jaureguizar N, Calvo R, Suarez E, Quintana, Razcka E, Lukas J. Altered disposition and effect of lerisetron in rats with elevated Alpha-1-acid glycoprotein. Pharm Res 2001; 18: 838-45.
60. Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT. Binding to serum alpha 1- acid glycoprotein and effect of beta- adrenoceptor antagonists in rats with inflammation. Br J Pharmacol 1986; 88: 697-705.
61. Keyler DE, Pentel PR, Haughey DB. Pharmacokinetics and toxicity of high-dose human alpha 1-acid glycoprotein infusion in the rat. J Pharm Sci 1987; 76: 101-4.
62. Oie S, Jacobson MA, Abrams DI. Alpha-1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993; 5: 531-33.
63. Bilello JA, Bilello PA, Stellrecht K, Leonard J, Norbeck DW, Kempf DJ, et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40: 1491-7.
64. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-35.
65. Sadler BM, Gillotin C, Lou Y, Stein DS. In vivo effect of alpha-1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45: 852-6.
66. Merry C, Mulcaby F, Gibbons S, Loyd J, Barry M, Back D. Alpha-1-acid glycoprotein concentrations in HIV disease-implications for treatment with protease inhibitors. AIDS 1996; 10: S24.
67. Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004; 26: 35-9.
68. Soldin SJ, Rakhmanina NY, Spiegel HM, Sever JL. Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience. Ther Drug Monit 2004; 26: 107-9.
69. van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boor AG, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 2001; 15: 483-91.
70. Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E, Bastie JN, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo. Biochem Pharmacol 2003; 66: 1907-13.
71. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, et al. α1 acid clycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic mycloid leukemia patients. Clin Cancer Res 2003; 9: 625-32.
72. Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res 1999; 59: 1054-60.
73. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001 15; 19: 4065-73.
74. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003; 39: 1105-14.
75. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991; 50: 385-93.
76. Toffoli G, Corona G, Basso B, Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004; 43: 441-66.
77. Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996;14(2): 147-51.
78. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72.
79. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003; 74: 364-71.
80. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68: 677-87.
81. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96.
82. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003; 9: 1077-82.
83. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005; 77: 43-53.
84. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, et al. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 2001; 29: 299-303.
85. Garrido MJ, Valle M, Calvo R, Troconiz IF. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 1999; 288: 179-87.
86. Jaureguizar N, Calvo R, Suarez E, Quintana, Razcka E, Lukas J. Altered disposition and effect of lerisetron in rats with elevated Alpha-1-acid glycoprotein. Pharm Res 2001; 18: 838-845.
87. Holladay JW, Dewey MJ, Yoo SD. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. Drug Metab Dispos 1998; 26: 20-4.
88. Aguirre C, Troconiz I, Valdivieso A, Jiménez R, González JP, Gómez E, et al. Pharmacokinetics and Pharmacodynamics of penbutolol in healthy and cancer subjects. Res Comm Mol Pathol Pharmacol 1996; 92: 53-72.
89. Fleming RA, Arbuck SG, Stewart CF. Interspecies differences in in vitro etoposide plasma protein binding. Biochem Pharmacol 1991; 42: 2246-9.
90. Reigner BG, Blesch KS. Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 2002;57: 835-45.
91. Chung SM, Park EJ, Swanson SM, Wu TC, Chiou WL. Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model. Pharm Res 2001; 18: 544-7.
92. Jaureguizar N, Calvo R, Suárez E, Quintana A, Razcka E, Lukas J. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist in rats. J Pharm Sci 2002; 91: 41-52
93. Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. J Med Chem 1997; 40: 586-93.
94. Ortega F, Calvo R, Lucero ML, Gonzalo A, Orjales A, Quintana A. Metabolism pattern characteristics of lerisetron in rats. Met Fin Exp Clin Pharm 2002; 24(Suppl A): 118.
95. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 1991; 257: 472-8.
96. van Schaick EA, de Greef HJ, Ijzerman AP, Danhof M. Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. J Pharmacokinet Biopharm 1997; 25: 673-94.
97. Jurgens G, Graudal NA, Kampmann JP. Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet 2003; 42: 647-63.
98. Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988; 10: 133-43.
99. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit 2002; 24: 74-80.
100. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137-57.
101. Akhlaghi F, Ashley JJ, Keogh AM, Brown KF. Indirect estimation of the unbound fraction of cyclosporine in plasma. Ther Drug Monit 1998; 20: 301-8.
102. Echizen H, Ishikawa S, Koike K, Ishizaki T. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations. Ther Drug Monit 1995; 17: 145-52.
103. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001; 23: 263-7.
104. Rodriguez M, Carlos MA, Ortega I, Suarez E, Calvo R, Lukas JC. Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. Pharm Res 2002; 19: 858-67.
105. Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol 2004; 44: 293-304.
106. Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: A multicenter study. Anesthesiology 2000; 92: 727-38.
107. Jauregizar N, Quintana A, Suarez E, Raczka E, de la Fuente L, Calvo R. Age related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: A population pharmacokinetic model. Gerontology 2003; 49: 205-14.
108. Jauregizar N, Wald JA, Astobieta A, Rodriguez Sasiain JM, Lukas JC, Calvo R. Population pharmacokinetics of netilmicin in short-term prophylactic treatment. Br J Clin Pharmacol 2003; 55: 552-9.
109. Foster DJ, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742-55.
110. Ma JD, Nafziger AN, Bertino JS Jr. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 2004; 44: 447-56.
111. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications. Clin Pharmacokinet 2004; 43: 553-76.
112. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59-98.
113. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003; 56: 205-13.
114. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004; 57: 756-63.
115. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000; 68: 541-55.
116. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
117. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Design 2004; 10(13): 1493-503.
118. Milligan G, Feng GJ, Ward RJ, Sartania N, Ramsay D, McLean AJ, et al. G protein-coupled receptor fusion proteins in drug discovery. Curr Pharm Design 2004; 10(17): 1989-2001.
119. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Design 2003; 9(11): 891-902.